The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care

[1]  Robert A Larsen,et al.  The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization. , 2008, AIDS patient care and STDs.

[2]  D. Kroetz,et al.  Adherence-resistance relationships to combination HIV antiretroviral therapy , 2007, Current HIV/AIDS reports.

[3]  R. Steinbrook.  Thailand and the compulsory licensing of efavirenz. , 2007, The New England journal of medicine.

[4]  D. Mcintyre,et al.  The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa – a primary data analysis , 2006, Cost effectiveness and resource allocation : C/E.

[5]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[6]  A. Davidson,et al.  Durability of adherence to antiretroviral therapy on initial and subsequent regimens. , 2006, AIDS patient care and STDs.

[7]  M. Eaddy,et al.  Methods for Evaluating Patient Adherence to Antidepressant Therapy: A Real-World Comparison of Adherence and Economic Outcomes , 2006, Medical care.

[8]  Jerome H. Carter,et al.  Distribution of health care expenditures for HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  L. Bekker,et al.  Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa , 2005, PLoS medicine.

[10]  A. Davidson,et al.  Selective Drug Taking During Combination Antiretroviral Therapy in an Unselected Clinic Population , 2005, Journal of acquired immune deficiency syndromes.

[11]  T. Flanigan,et al.  Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients , 2005, AIDS.

[12]  A. Wu,et al.  Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence , 2005, AIDS care.

[13]  J. Ka,et al.  Comparing total health care costs and treatment patterns of HIV patients in a managed care setting , 2004 .

[14]  N. Kumarasamy,et al.  Generic antiretroviral drugs—will they be the answer to HIV in the developing world? , 2004, The Lancet.

[15]  M. Peeters,et al.  Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial , 2004, The Lancet.

[16]  A. Vanderplas,et al.  The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment , 2004 .

[17]  M. Postma,et al.  A multicentre study of patient survival, disability, quality of life and cost of care , 2004, PharmacoEconomics.

[18]  A. Vanderplas,et al.  Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization , 2003 .

[19]  Milton C Weinstein,et al.  Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. , 2003, The American journal of medicine.

[20]  Julio S. G. Montaner,et al.  Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.

[21]  Evan Wood,et al.  Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? , 2003, AIDS.

[22]  P. Gabow,et al.  Denver Health: A Model for the Integration of a Public Hospital and Community Health Centers , 2003, Annals of Internal Medicine.

[23]  R. Hogg,et al.  Virologic and Immunologic Response, Clinical Progression, and Highly Active Antiretroviral Therapy Adherence , 2002, Journal of acquired immune deficiency syndromes.

[24]  Dawn M Gencarelli.  Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? , 2002, NHPF issue brief.

[25]  B. Yip,et al.  Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up , 2002, AIDS.

[26]  A. Zolopa,et al.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.

[27]  M. Weinstein,et al.  Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy , 2001, Antiviral therapy.

[28]  D. Skiest,et al.  Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. , 2001 .

[29]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[30]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.

[31]  M. Youle,et al.  Assessing the cost‐effectiveness of HAART for adults with HIV in England , 2001, HIV medicine.

[32]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[33]  A. Gafni,et al.  Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. , 1999, AIDS.

[34]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[35]  A. Davidson,et al.  Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. , 1993, Archives of internal medicine.

[36]  D. B. Duncan.  MULTIPLE RANGE AND MULTIPLE F TESTS , 1955 .

[37]  J. Puig-Junoy,et al.  Análisis coste-efectividad de la adhesión inicial a la terapia antirretroviral entre individuos infectados por el VIH en Belo Horizonte, Brasil , 2006 .

[38]  Thomas Fleming,et al.  Red book : pharmacy's fundamental reference , 2004 .